A Phase 2 interventional study of Placebo (blinded) and Vancomycin (blinded) in Ulcerative Colitis (UC) and Primary Sclerosing Cholangitis (PSC), sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by McMaster University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.
Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 219th largest by planned enrollment of the 227 interventional ones that give a count, is one of 16 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 54 of the 83 other live ones, and was the 254th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
AbbVie · Sites in Canada, United States, Israel and 2 more countries
Ages 18–75
Pfizer · Sites in Canada, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Canada, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 90 · Phase 3 86 · Phase 4 12
First in 2000; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 162 across the 227 interventional studies, 197 across the 38 observational. Of the 165 that completed or were terminated, 95 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
181 of 265 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
27 of the studies in Colitis, Ulcerative with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT06660693Phase 3McMaster UniversityComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | 2027-05 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 27 to your calendar (.ics) → With an account.
Among the 265 studies in Colitis, Ulcerative with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are:
Participants will be compared to see if vancomycin works better than placebo. Participants will:
The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.
This is an investigator-initiated feasibility study designed to rigorously characterize clinical response signals, safety parameters, and feasibility metrics in adults with co-existing PSC and UC, a population where microbiome-targeted immune modulation is hypothesized to influence disease activity.
Randomization \& Allocation Governance
Clinical Visit \& Assessment Schedule
Participants will complete a structured study visit pathway:
Adherence \& Safety Surveillance
Data Capture \& Monitoring Integrity
Safety Governance Structure
The DSMC will provide independent oversight and safety adjudication:
Regulatory \& Ethical Compliance
The trial will follow all institutional and international regulatory standards:
Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks blinded placebo followed by optional 4 weeks open-label vancomycin.
Drug: Placebo (blinded) · Drug: Vancomycin (open-label extension)
4 weeks blinded oral vancomycin followed by optional additional 4 weeks open-label vancomycin.
Drug: Vancomycin (blinded) · Drug: Vancomycin (open-label extension)
Identical placebo capsule administered orally twice daily for 4 weeks.
Vancomycin 250 mg administered orally twice daily for 4 weeks.
Vancomycin 250 mg administered orally twice daily for 4 weeks (optional extension offered to both arms).
Recruitment rate
Proportion of eligible participants who provide consent and are enrolled in the study (number enrolled ÷ number eligible approached), with a target of 14 participants within 12 months.
Time frame: 12 months
Retention rate
Proportion of enrolled participants who complete all protocol-specified study visits and assessments at 12 months (number completing all follow-up visits ÷ number enrolled).
Time frame: 12 months
Treatment adherence
Proportion of prescribed oral vancomycin doses taken over the treatment period, assessed by pill counts and/or medication diary (number of doses taken ÷ number of doses prescribed).
Time frame: 12 months
Protocol compliance with study procedures
Proportion of participants with all required visits, laboratory tests, and assessments completed per protocol (number fully compliant ÷ number enrolled); may also include rate of major protocol deviations.
Time frame: 12 months
Incidence of adverse events and serious adverse events
Proportion of participants with at least one treatment-emergent adverse event (AE) or serious adverse event (SAE)
Time frame: 12 months
Severity and type of adverse events
Number of treatment-emergent AEs and SAEs by maximum severity grade (mild/moderate/severe) and type (MedDRA preferred term).
Time frame: 12 months
Relationship of adverse events to oral vancomycin
Proportion of AEs/SAEs assessed by investigator as related to intervention (number related ÷ total events).
Time frame: 12 months
Patient-reported tolerability of oral vancomycin
Mean score of side effect frequency and impact on 0-10 scale (0=no impact, 10=worst impact) via study questionnaire.
Time frame: 12 months
Exploratory Endpoints (Change in Mayo Score from baseline)
Change in partial Mayo Clinic Score (range 0-12 points, higher scores indicate greater ulcerative colitis disease activity) from baseline to 12 months.
Time frame: 12 months
Exploratory Endpoints (Change in serum liver enzymes from baseline)
Change in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (units: U/L) from baseline to 12 months.
Time frame: 12 months
Exploratory Endpoints (Change in gut microbiome diversity from baseline)
Change in gut microbiome diversity (Shannon index, unitless) measured by 16S rRNA sequencing of fecal samples from baseline to 12 months.
Time frame: 12 months
Exploratory Endpoints (Change in fecal bile acids from baseline)
Change in total fecal bile acid concentration (units: μmol/g) measured by mass spectrometry from baseline to 12 months.
Time frame: 12 months
Exploratory Endpoints (Change in fecal short chain fatty acids from baseline)
Change in total fecal short chain fatty acid concentration (units: μmol/g), including acetate, propionate, and butyrate, measured by gas chromatography from baseline to 12 months.
Time frame: 12 months
Plan to share: Yes — Data sharing policies would follow institutional and regulatory standards on data confidentiality and sharing. De-identified data shared upon request to qualified researchers with appropriate data use agreements, respecting participant confidentiality and ethical approvals. Patient demographics, primary data and data analysis can be shared.
Supporting information: Study protocol
Time frame: Start Date is estimated in January 2026 - end date is estimated in December 2026.
Access criteria: Access to IPD and supporting study documents will generally limited to qualified researchers who submit a reasonable scientific request and have the necessary expertise. The data shared would be de-identified or anonymized to protect participant confidentiality. Researchers might be granted access under data use agreements that specify the terms of use, including restrictions on re-identification and further sharing. Access is often facilitated through secure data repositories or by request through the trial sponsor or coordinating research unit after review and approval of the request.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 18 months is below that.
Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jan 2026 → Jun 2026, primary completion Dec 2026 → Dec 2027 and completion Mar 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin